(Q36696731)

15 August 2017

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours (English)

1 reference

15 August 2017

Wall L

1

1 reference

15 August 2017

Talbot DC

series ordinal

2

1 reference

15 August 2017

Bradbury P

series ordinal

3

1 reference

15 August 2017

Jodrell DI

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

90

1 reference

15 August 2017

4

1 reference

15 August 2017

800-804

1 reference

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410175

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410175

A phase II trial of marimastat in advanced pancreatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410175

Matrix metalloproteinases: biologic activity and clinical implications

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410175

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410175

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410175

Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2410175

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14970856

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14970856

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6601594

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

14970856

1 reference